Date Added: 14/09/2017
Date Updated: 14/09/2017
Allogeneic mesenchymal stem cell and autologous T-cell therapies for the treatment of refractory Crohn’s disease
Specialties: Gastrointestinal, pancreatic and liver disease - Haematology & blood products
Technology Type: Procedures
Stage of development: Other
Stage of EAA: Assessment Complete
Allogeneic mesenchymal stem cell and T-cell therapies to treat refractory Crohn’s disease are still in a developmental phase, with no indication to suggest any influence on clinical practice in Australia and New Zealand. Most evidence on the technologies is limited to case series.
Therapies such as stem cell treatment should be considered investigational and would only be applicable to a small proportion of patients with refractory Crohn’s disease who had failed conventional treatments.